We are live on ! Find out more
AGIO icon

Agios Pharmaceuticals
AGIO

144 hedge funds and large institutions have $1.46B invested in Agios Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 56 increasing their positions, 46 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 46

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1.02% less ownership

Funds ownership: 106.81% → 105.79% (-1%)

5% less funds holding

Funds holding: 152 → 144 (-8)

13% less capital invested

Capital invested by funds: $1.68B → $1.46B (-$216M)

41% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 17

48% less call options, than puts

Call options by funds: $6.15M | Put options by funds: $11.9M

Holders
144
Holders Change
-8
Holders Change %
-5.26%
% of All Funds
2.29%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
10
Increased
56
Reduced
46
Closed
17
Calls
$6.15M
Puts
$11.9M
Net Calls
-$5.73M
Net Calls Change
+$996K

Top Buyers

1
DTC
Deep Track Capital
Connecticut
+$11.2M
2
Macquarie Group
Macquarie Group
Australia
+$9.66M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$8.8M
4
FLSM
Frazier Life Sciences Management
California
+$7.72M
5
Citadel Advisors
Citadel Advisors
Florida
+$6.39M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$17.6M
2
First Trust Advisors
First Trust Advisors
Illinois
-$10.2M
3
State Street
State Street
Massachusetts
-$8.4M
4
UBS AM
UBS AM
Illinois
-$5.37M
5
Man Group
Man Group
United Kingdom
-$4.51M
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$135M -$1.38M -52,000 -0.9%
Wellington Management Group
2
Wellington Management Group
Massachusetts
$129M -$17.6M -666,565 -11%
BlackRock
3
BlackRock
New York
$115M -$1.99M -75,263 -2%
BG
4
Bellevue Group
Switzerland
$99.3M – – –
AC
5
Armistice Capital
New York
$82.3M +$1.8M +68,000 +2%
FCM
6
Farallon Capital Management
California
$68.1M +$1.64M +62,000 +2%
RSCM
7
Rock Springs Capital Management
Maryland
$67.1M +$632K +23,894 +0.9%
JP Morgan Chase
8
JP Morgan Chase
New York
$61.1M -$665K -25,154 -1%
Dimensional Fund Advisors
9
Dimensional Fund Advisors
Texas
$60.9M +$5.16M +195,073 +9%
State Street
10
State Street
Massachusetts
$56M -$8.4M -317,635 -12%
Macquarie Group
11
Macquarie Group
Australia
$49.3M +$9.66M +365,062 +22%
First Trust Advisors
12
First Trust Advisors
Illinois
$43.9M -$10.2M -385,409 -18%
EAM
13
Erste Asset Management
Austria
$41.9M – – –
T. Rowe Price Associates
14
T. Rowe Price Associates
Maryland
$40.2M +$8.8M +332,718 +26%
ACH
15
ArrowMark Colorado Holdings
Colorado
$38.9M +$2.78K +105 +0%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$29.7M +$1.09M +41,293 +4%
BNP Paribas Asset Management
17
BNP Paribas Asset Management
France
$24.8M +$1.96M +74,144 +8%
T. Rowe Price Investment Management
18
T. Rowe Price Investment Management
Maryland
$23M – – –
Pictet Asset Management
19
Pictet Asset Management
Switzerland
$22M +$23.6M +890,684 New
Fisher Asset Management
20
Fisher Asset Management
Washington
$20.2M -$1.42M -53,680 -6%
Goldman Sachs
21
Goldman Sachs
New York
$19.9M +$154K +5,825 +0.7%
Northern Trust
22
Northern Trust
Illinois
$15.2M -$2.57M -96,969 -14%
Deutsche Bank
23
Deutsche Bank
Germany
$14.4M +$95.9K +3,626 +0.6%
SCM
24
Suvretta Capital Management
New York
$11.2M – – –
Charles Schwab
25
Charles Schwab
California
$11.2M +$381K +14,420 +3%
1
2 3 4 5

AGIO Hedge Fund Activity: Q3 2023 in Review

144 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q3 2023, worth a combined $1.46B — down 13% from $1.68B a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of AGIO and 10 opened new positions — a net loss of 7 holders — while 46 trimmed existing stakes and 56 added.

The largest buyer was Deep Track Capital, opening a new position worth an estimated $11.2M. The largest seller was Wellington Management Group, cutting an estimated $17.6M.

  • 144 institutional investors held Agios Pharmaceuticals (AGIO) as of Q3 2023, down from 152 in Q2 2023.
  • Funds reported $1.46B of Agios Pharmaceuticals stock for Q3 2023, down 13% quarter-over-quarter.
  • 10 funds opened new Agios Pharmaceuticals positions in Q3 2023 and 17 closed out, a net change of -7 holders.
  • The largest Agios Pharmaceuticals buyer in Q3 2023 was Deep Track Capital, an estimated $11.2M added.
  • The largest Agios Pharmaceuticals seller in Q3 2023 was Wellington Management Group, an estimated $17.6M sold.

Based on aggregated 13F filings for Q3 2023.